Novel focal therapy treatment options for prostate cancer. Issue 2 (March 2018)

• Record Type: Journal Article
• Authors: Werntz, Ryan P.; Eggener, Scott E.
• Is Part Of: Current opinion in urology. Volume 28:Issue 2(2018:Mar.)
• Publication Date: 2018-03
• Subjects: focal therapy -- MRI -- prostate cancer; Urology -- Periodicals; Review Literature -- Bibliography; Review Literature -- Periodicals; Male Urogenital Diseases -- Bibliography; Male Urogenital Diseases -- Periodicals; Female Urogenital Diseases -- Bibliography; Female Urogenital Diseases -- Periodicals; Urologic Diseases -- Bibliography; Urologic Diseases -- Periodicals; Periodicals; 616.6005
• DOI: 10.1097/MOU.0000000000000469
• Languages: English
• ISSNs: 1473-6586

Abstract

Abstract : Purpose of review: Examine and discuss novel focal therapy treatment options for prostate cancer. Recent findings: With the widespread adoption of mpMRI-guided biopsies for prostate cancer, use of image-guided treatment of prostate cancer has increased. Focal therapies leading to partial gland ablation such as partial prostatectomy, focal laser ablation, irreversible electroporation, vascular targeted photodynamic therapy, and focal radiofrequency ablation have emerged and begun to be properly evaluated. This review covers published phase 1 and 2 trials of each treatment and discusses potential limitations of each modality. Summary: Focal therapy of prostate cancer is being actively investigated. On the basis of limited published data, the treatments appear to be well tolerated and have an acceptable side effect profile. Importantly, short-term oncologic control has been mixed and there are no long-term outcomes. The acquisition of more data is essential to evaluate these novel technology platforms.